Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL

Julio Chavez, MD
Published: Monday, Aug 14, 2017


Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Sequential treatment is the future of CLL, says Chavez, including the combination of ibrutinib plus venetoxclax and combinations with monoclonal antibodies.

Ibrutinib plus venetoclax is an interesting combination, Chavez says, and further results will be presented at the 2017 ASH Annual Meeting to confirm its potential in this disease.
 

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Sequential treatment is the future of CLL, says Chavez, including the combination of ibrutinib plus venetoxclax and combinations with monoclonal antibodies.

Ibrutinib plus venetoclax is an interesting combination, Chavez says, and further results will be presented at the 2017 ASH Annual Meeting to confirm its potential in this disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x